Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Joyce S, Plested"'
Autor:
Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Lee Fairlie, Umesh Lalloo, Mduduzi S. L. Masilela, Dhayendre Moodley, Sherika Hanley, Leon Frederik Fouche, Cheryl Louw, Michele Tameris, Nishanta Singh, Ameena Goga, Keertan Dheda, Coert Grobbelaar, Natasha Joseph, Johan J. Lombaard, Rosie Mngqibisa, As’ad Ebrahim Bhorat, Gabriella Benadé, Natasha Lalloo, Anna Pitsi, Pieter-Louis Vollgraaff, Angelique Luabeya, Aliasgar Esmail, Friedrich G. Petrick, Aylin Oommen Jose, Sharne Foulkes, Khatija Ahmed, Asha Thombrayil, Dishiki Kalonji, Shane Cloney-Clark, Mingzhu Zhu, Chijioke Bennett, Gary Albert, Alex Marcheschi, Joyce S. Plested, Susan Neal, Gordon Chau, Iksung Cho, Louis Fries, Greg M. Glenn, Shabir A. Madhi
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study’s pre-crossover/booster pha
Externí odkaz:
https://doaj.org/article/90d0e4a6be6e439a95268e85ec023ca2
Autor:
Timothy S. Vincent, Mingzhu Zhu, Anand Parekh, Urvashi Patel, Shane Cloney-Clark, Andrew Klindworth, David Silva, Andrew Gorinson, Karlee Miranda, Mi Wang, Zachary Longacre, Bin Zhou, Iksung Cho, Rongman Cai, Raj Kalkeri, Louis Fries, Vivek Shinde, Joyce S. Plested
Publikováno v:
Microorganisms, Vol 12, Iss 11, p 2358 (2024)
Currently available seasonal influenza vaccines confer variable protection due to antigenic changes resulting from the accumulation of diverse mutations. The analysis of new seasonal influenza vaccines is challenging in part due to the limitations of
Externí odkaz:
https://doaj.org/article/5cb3b7d14c4c4c02aa3aed68d6492e2e
Autor:
Prasad S. Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Sonali Kar, Sidram Raut, Praveen Kulkarni, Aditi Apte, Ashish Bavdekar, Hira Lal Bhalla, Joyce S. Plested, Shane Cloney-Clark, MingZhu Zhu, Raj Kalkeri, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ranga S. Sannidhi, Punjita Baranwal, Chetanraj Bhamare, Abhijeet Dharmadhikari, Manish Gupta, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, COVOVAX-Booster Study Group
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed with viral vector and
Externí odkaz:
https://doaj.org/article/9a552b8a78384202b575842720c27791
Autor:
Zhaohui Cai, Raj Kalkeri, Mi Wang, Benjamin Haner, Dominic Dent, Bahar Osman, Paul Skonieczny, Jeremy Ross, Sheau-Line Feng, Rongman Cai, Mingzhu Zhu, Shane Cloney-Clark, Joyce S. Plested
Publikováno v:
Microorganisms, Vol 12, Iss 6, p 1201 (2024)
The evaluation of coronavirus disease 2019 (COVID-19) vaccine immunogenicity remains essential as the severe acute respiratory syncytial virus 2 (SARS-CoV-2) pandemic continues to evolve and as additional variants emerge. Neutralizing antibodies are
Externí odkaz:
https://doaj.org/article/5ca8ebd8330b4699901488187db063f4
Autor:
Zhaohui Cai, Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Benjamin Haner, Mi Wang, Bahar Osman, Dominic Dent, Sheau-Line Feng, Zach Longacre, Greg Glenn, Joyce S. Plested
Publikováno v:
Microorganisms, Vol 12, Iss 3, p 501 (2024)
Neutralizing antibody responses from COVID-19 vaccines are pivotal in conferring protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Effective COVID-19 vaccines and assays measuring neutralizing antibodies against emergin
Externí odkaz:
https://doaj.org/article/5858950851b847d3a887997ce88e0ecc
Autor:
Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi
Publikováno v:
The Lancet Regional Health - Southeast Asia, Vol 10, Iss , Pp 100139- (2023)
Summary: Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study
Externí odkaz:
https://doaj.org/article/82d9dafd89e042aabbf3940c237b71b1
Autor:
Mingzhu Zhu, Shane Cloney-Clark, Sheau-line Feng, Anand Parekh, Drew Gorinson, David Silva, Paul Skonieczny, Adjele Wilson, Raj Kalkeri, Wayne Woo, Miranda R. Cai, Louis Fries, Greg Glenn, Joyce S. Plested
Publikováno v:
Microorganisms, Vol 11, Iss 7, p 1789 (2023)
As the COVID-19 pandemic continues, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge. Immunogenicity evaluation of vaccines and identification of correlates of protection for vaccine effectiveness is critica
Externí odkaz:
https://doaj.org/article/7031ad406929446f93365e8f5df4cb5a
Autor:
Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Edmond Massuda, Urvashi Patel, Andrew Klindworth, Michael J. Massare, Rongman Cai, Louis Fries, Greg Glenn, Raj Kalkeri
Publikováno v:
Microorganisms, Vol 11, Iss 2, p 368 (2023)
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show immune evasion of vaccine-derived immunity, highlighting the need for better clinical immunogenicity biomarkers. To address this need, an enzyme-linked immunosorbe
Externí odkaz:
https://doaj.org/article/eccebede663c4ad0a28cb35070d10ef6
Autor:
Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested, Iksung Cho, Andreana Robertson, Filip Dubovsky, Gregory M Glenn, nCoV-101 Study Group
Publikováno v:
PLoS Medicine, Vol 18, Iss 10, p e1003769 (2021)
BackgroundNVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.Methods and findingsThe phase 2 component of our r
Externí odkaz:
https://doaj.org/article/d8f07241dfa4407b835b334d15d8c76c
Autor:
Katia Alves, Joyce S. Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Kathy Smith, Alex Marcheschi, Susan Pfeiffer, Heather McFall, Gale Smith, Gregory M. Glenn, Filip Dubovsky, Raburn M. Mallory
Publikováno v:
New England Journal of Medicine. 388:857-859
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d72458360ab8561e0fa81d0fad4dcecf
https://doi.org/10.1056/nejmc2215509
https://doi.org/10.1056/nejmc2215509